Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANTEOTECH LTD Capital/Financing Update 2015

Dec 22, 2015

64304_rns_2015-12-22_33e40ad5-6d62-4db1-9575-9af88b5aea7f.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [315 x 91] intentionally omitted <==

ANTEO CLOSES ENTITLEMENT ISSUE AND PROPOSES SHARE PLACEMENT AS PART OF OVERALL FUNDING PACKAGE FOR DIASOURCE ACQUISITION

23 December, 2015 – Anteo Diagnostics (ASX: ADO) (Anteo or the Company) is pleased to announce that it has successfully closed its Entitlement Issue and is finalising underwriting and share placements.

The Entitlement Issue raised $5,235,210.75 (for 70,042,810 shares) in subscriptions from eligible Anteo shareholders resulting in a shortfall of approximately $6,765,217, which is intended to be satisfied through the subscription by sub-underwriters pursuant to the terms of the Underwriting Agreement previously announced. The Entitlement Issue shares will be issued to shareholders on 29 December, 2015.

The underwriting arrangements are conditional upon the Company entering into formal binding documentation with the €10million Convertible Note lender

The Company and the Underwriter have formal commitments from investors including subunderwriters, institutional and wholesale investors of approximately $8 million, which, if the conditions of the Underwriting Agreement are satisfied will result in approximately $13.2 million being raised ($12.018 million from the Entitlement Issue and a Share Placement of $1.2 million, which the Directors will undertake on the same terms as the Entitlement Issue to satisfy the additional demand). This amount exceeds the targeted $12.018 million of the Entitlement Issue. The Directors intend to accept all funds committed.

Anteo is working with both the Underwriter and the Convertible Note investor to finalise documentation to complete the transaction.

For further information, see our website (www.anteodx.com) or contact the persons outlined below.

Company Media and Investor Relations
Dr. Geoff Cumming, Chief Executive OfficerT: + 61 7 3219 0085Richard Martin, Chief Financial OfficerT: + 61 7 3219 0085 Jane Lowe, IR DepartmentE: [email protected]T: + 61 411 117 774

==> picture [596 x 138] intentionally omitted <==